FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track
NeOnc (NASDAQ: NTHI) secured an FDA Type B End-of-Phase meeting, early January 2027, to discuss a potential accelerated approval pathway for NEO100
NeOnc (NASDAQ: NTHI) secured an FDA Type B End-of-Phase meeting, early January 2027, to discuss a potential accelerated approval pathway for NEO100